Accelerated TMS for Apathy in Parkinson's Disease

This trial explores a new method to assist people with Parkinson's Disease who experience strong feelings of apathy—a lack of interest or enthusiasm. The treatment under investigation is called accelerated iTBS (intermittent theta-burst stimulation), a type of non-invasive brain stimulation designed to boost activity in a brain area linked to motivation. Participants will attend six treatment sessions over two weeks. This trial might suit individuals with Parkinson's Disease who often feel uninterested or disengaged from daily activities and have a caregiver for support. As an unphased trial, this study offers a unique opportunity to contribute to groundbreaking research that could enhance the quality of life for those with Parkinson's Disease.

The trial requires that your Parkinson's Disease medications remain stable, so you should not stop taking them.

Studies have shown that intermittent theta-burst stimulation (iTBS) is generally safe and well-tolerated. The FDA has approved iTBS for treating depression, indicating a strong safety record. Research on its use for Parkinson's disease (PD) shows that patients usually handle it well, experiencing only mild side effects. Common side effects include headaches and scalp discomfort, which are typically temporary and not severe. In some studies, patients experienced minor facial twitching or felt tired after sessions. Overall, iTBS appears to be a promising and safe option for treating symptoms in PD.¹²³⁴⁵

Most treatments for apathy in Parkinson's disease rely on medications or behavioral therapies, but accelerated intermittent theta-burst stimulation (iTBS) offers a new approach. This treatment uses rapid magnetic pulses targeting the brain's left dorsomedial prefrontal cortex, an area linked to motivation and decision-making. Researchers are excited because iTBS can deliver results more quickly than traditional methods, with sessions spread over just two weeks. Plus, it offers a non-invasive option with the potential to significantly improve quality of life for those with Parkinson's.

Research has shown that intermittent theta-burst stimulation (iTBS) can alleviate symptoms of Parkinson's Disease. In this trial, participants in the TMS group will receive accelerated iTBS targeting the left dorsomedial prefrontal cortex. One study found that iTBS improved movement problems in Parkinson's patients, especially when they were not taking their medication. Another study discovered that iTBS, when aimed at specific brain regions, could enhance motivation, which is crucial for reducing apathy. These findings suggest that iTBS might alleviate apathy by activating brain areas related to motivation and movement. Additionally, iTBS is considered safe and generally well-tolerated, with side effects such as mild headaches or scalp irritation. Overall, early results are promising for using iTBS to address apathy in Parkinson's Disease.²⁶⁷⁸⁹